Use of a soluble epoxide hydrolase inhibitor as an adjunctive analgesic in a horse with laminitis.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Veterinary Anaesthesia and Analgesia

• Publication date

  2013-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/vaa.12030PMID 23463912PMCID PMC3956586
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Acute augmentation of epoxygenated fatty acid levels rapidly reduces pain-related behavior in a rat model of type I diabetes

  2012cited by this paper
• Pharmacokinetics and in vivo potency of soluble epoxide hydrolase inhibitors in cynomolgus monkeys

  2012cited by this paper
• Analysis of gabapentin in equine plasma with measurement uncertainty estimation by liquid chromatography-tandem mass spectrometry.

  2011cited by this paper
• Epoxygenated fatty acids and soluble epoxide hydrolase inhibition: novel mediators of pain reduction.

  2011cited by this paper
• Soluble epoxide hydrolase inhibition, epoxygenated fatty acids and nociception.

  2011cited by this paper
• Unsaturated fatty acids and pain.

  2011cited by this paper
• Comparison of subjective scoring systems used to evaluate equine laminitis.

  2011cited by this paper
• Analgesia mediated by soluble epoxide hydrolase inhibitors is dependent on cAMP

  2011cited by this paper
• Lipid mediators in life science.

  2011cited by this paper
• Neuropathic pain management in chronic laminitis.

  2010influential reference
• Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs.

  2010cited by this paper
• Pharmacokinetic profile and behavioral effects of gabapentin in the horse.

  2010cited by this paper
• Pharmacological inhibition of the soluble epoxide hydrolase-from mouse to man.

  2010cited by this paper
• Naturally occurring monoepoxides of eicosapentaenoic acid and docosahexaenoic acid are bioactive antihyperalgesic lipids[S]

  2010cited by this paper
• Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases

  2009cited by this paper
• Mammalian epoxide hydrolases in xenobiotic metabolism and signalling

  2009cited by this paper
• Screening, quantification, and confirmation of phenylbutazone and oxyphenbutazone in equine plasma by liquid chromatography-tandem mass spectrometry.

  2009cited by this paper
• Development of a composite orthopaedic pain scale in horses.

  2008cited by this paper
• Soluble epoxide hydrolase and epoxyeicosatrienoic acids modulate two distinct analgesic pathways

  2008cited by this paper
• Gerry Brooks and epoxide hydrolases: four decades to a pharmaceutical.

  2008cited by this paper
• Orally bioavailable potent soluble epoxide hydrolase inhibitors.

  2007cited by this paper
• Lamellar pro-inflammatory cytokine expression patterns in laminitis at the developmental stage and at the onset of lameness: innate vs. adaptive immune response.

  2007cited by this paper
• The soluble epoxide hydrolase as a pharmaceutical target for hypertension.

  2007cited by this paper
• Gabapentin for the treatment of neuropathic pain in a pregnant horse.

  2007cited by this paper
• Neuropathic changes in equine laminitis pain

  2007cited by this paper
• Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosatrienoic acids (EETs).

  2007cited by this paper
• Pentoxifylline attenuates the development of hyperalgesia in a rat model of neuropathic pain.

  2007cited by this paper
• Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors

  2006influential reference
• Inhibition of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia and mechanical allodynia in a rat model of inflammatory pain.

  2006cited by this paper
• Predisposition for venoconstriction in the equine laminar dermis: implications in equine laminitis.

  2006cited by this paper
• Immune and inflammatory mechanisms in neuropathic pain.

  2006cited by this paper
• Peptidyl-urea based inhibitors of soluble epoxide hydrolases.

  2006cited by this paper
• Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles.

  2005cited by this paper
• Soluble epoxide hydrolase is a therapeutic target for acute inflammation.

  2005cited by this paper
• COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam: an in vitro analysis.

  2005cited by this paper
• Antihyperalgesic effect of pentoxifylline on experimental inflammatory pain

  2004cited by this paper
• Effects of glycopyrrolate on cardiorespiratory function in horses anesthetized with halothane and xylazine.

  2004cited by this paper
• Chronic laminitis: current treatment strategies.

  2003cited by this paper
• Diagnosing and treating pain in the horse. Where are we today?

  2002cited by this paper
• Hepatic and pulmonary enzyme activities in horses.

  2000cited by this paper
• Gabapentin enhances the analgesic effect of morphine in healthy volunteers.

  2000cited by this paper
• Gabapentin Enhances the Analgesic Effect of Morphine in Healthy Volunteers

  2000cited by this paper
• Soluble Epoxide Hydrolase Regulates Hydrolysis of Vasoactive Epoxyeicosatrienoic Acids

  2000cited by this paper
• Pharmacologic and alternative therapies for the horse with chronic laminitis.

  1999cited by this paper
• The pathophysiology of developmental and acute laminitis.

  1999cited by this paper
• Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids.

  1999cited by this paper
• The role of vascular mechanisms in the development of acute equine laminitis.

  1993cited by this paper

• Coamorphous Solid Dispersion of a Soluble Epoxide Hydrolase Inhibitor t-TUCB with Amino Acid l-Arginine

  2025cites this paper
• Randomized, double‐blind, phase 1a single‐ascending dose and food effect studies assessing safety and pharmacokinetics of EC5026 in healthy volunteers

  2024cites this paper
• Regulatory lipid vicinal diols counteract the biological activity of epoxy fatty acids and can act as biomarkers and mechanisms for disease progression.

  2023cites this paper
• Effects of cyclooxygenase and soluble epoxide hydrolase inhibitors on apoptosis of cultured primary equine chondrocytes.

  2022cites this paper
• Sex-Specific Differences in Resolution of Airway Inflammation in Fat-1 Transgenic Mice Following Repetitive Agricultural Dust Exposure

  2022cites this paper
• Anti-nociceptive efficacy of the soluble epoxide hydrolase inhibitor t-TUCB in horses with mechanically induced lameness.

  2022cites this paper
• Schmerztherapie beim Patienten mit Hufrehe

  2022cites this paper
• Aflatoxin B1 exposure disrupts the intestinal immune function via a soluble epoxide hydrolase-mediated manner.

  2022cites this paper
• Inhibition of the Soluble Epoxide Hydrolase as an Analgesic Strategy: A Review of Preclinical Evidence

  2021cites this paper
• Pharmacology of the Equine Foot: Medical Pain Management for Laminitis.

  2021cites this paper
• Targeting Soluble Epoxide Hydrolase and Cyclooxygenases Enhance Joint Pain Control, Stimulate Collagen Synthesis, and Protect Chondrocytes From Cytokine-Induced Apoptosis

  2021cites this paper
• Pain Treatment in the Companion Canine Model to Validate Rodent Results and Incentivize the Transition to Human Clinical Trials

  2021cites this paper
• Activity of sEH and Oxidant Status during Systemic Bovine Coliform Mastitis

  2021cites this paper
• Movement to the Clinic of Soluble Epoxide Hydrolase Inhibitor EC5026 as an Analgesic for Neuropathic Pain and for Use as a Nonaddictive Opioid Alternative

  2021cites this paper
• Computational design of two new soluble epoxide hydrolase (sEH) inhibitors

  2020cites this paper
• Preparation and evaluation of soluble epoxide hydrolase inhibitors with improved physical properties and potencies for treating diabetic neuropathic pain.

  2020cites this paper
• Redox regulation of soluble epoxide hydroxylase does not affect pain behavior in mice.

  2020cites this paper
• Soluble Epoxide Hydrolase Regulation of Lipid Mediators Limits Pain

  2020cites this paper
• Selection of Potent Inhibitors of Soluble Epoxide Hydrolase for Usage in Veterinary Medicine

  2020cites this paper
• Epoxyeicosatrienoic acids: emerging therapeutic agents for central post-stroke pain.

  2020cites this paper
• Nitrogen Deficiency-Dependent Abiotic Stress Enhances Carotenoid Production in Indigenous Green Microalga Scenedesmus rubescens KNUA042, for Use as a Potential Resource of High Value Products

  2020cites this paper
• The molecular structure of an epoxide hydrolase from Trichoderma reesei in complex with urea or amide-based inhibitors.

  2019cites this paper
• Therapeutic developments in equine pain management.

  2019cites this paper
• Soluble epoxide hydrolase inhibitor, t-TUCB, protects against myocardial ischemic injury in rats

  2019cites this paper
• Equine Hoof Stratum Internum K14+CD105+ Progenitor Cells: Culture, Characterization, and Model of Epithelial to Mesenchymal Transition

  2019cites this paper
• Soluble Epoxide Hydrolase Inhibition for Ocular Diseases: Vision for the Future

  2019cites this paper
• Primary Care Clinical Guidelines: Analgesia.

  2019cites this paper
• Alleviation of Mechanical Allodynia by 14,15-Epoxyeicosatrienoic Acid in a Central Poststroke Pain Model: Possible Role of Allopregnanolone and δ-Subunit-Containing Gamma-Aminobutyric Acid A Receptors.

  2019cites this paper
• Microalga Scenedesmus bajacalifornicus BBKLP-07, a new source of bioactive compounds with in vitro pharmacological applications

  2019cites this paper
• Laminitis in horses

  2018cites this paper
• Recognizing and Treating Pain in Horses

  2018cites this paper
• Synthesis and Properties of N-[R-Adamantan-1(2)-yl]-N′-(2-fluorophenyl)ureas—Target-Oriented Soluble Epoxide Hydrolase Inhibitors

  2018cites this paper
• Pain management for laminitis in the horse

  2018cites this paper
• Pharmacokinetics and antinociceptive effects of the soluble epoxide hydrolase inhibitor t‐TUCB in horses with experimentally induced radiocarpal synovitis

  2018influential citation
• Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase.

  2018cites this paper
• Correction to Optimized Inhibitors of Soluble Epoxide Hydrolase Improve in Vitro Target Residence Time and in Vivo Efficacy

  2018cites this paper
• Substrate and inhibitor selectivity, and biological activity of an epoxide hydrolase from Trichoderma reesei

  2018cites this paper
• Synthesis and Properties of N-(R-Adamantan-1-ylalkyl)-N′-[3(4)-fluorophenyl]thioureas—Target-Oriented Human Soluble Epoxide Hydrolase (hsEH) Inhibitors

  2018cites this paper
• Update in advances in pain management for the equine practitioner

  2018cites this paper
• Synthesis and properties of 1-(R-adamant-1-yl)-3-(1-propionylpiperidin-4-yl)ureas and 4-({4-[3-(R-adamant-1-yl)ureido]cyclohexyl}oxy)benzoic acids, efficient target-oriented human soluble epoxide hydrolase inhibitors

  2017cites this paper
• Soluble epoxide hydrolase activity and pharmacologic inhibition in horses with chronic severe laminitis

  2017cites this paper
• Report of the 13th Annual International Pachyonychia Congenita Consortium Symposium

  2017cites this paper
• Occurrence of urea-based soluble epoxide hydrolase inhibitors from the plants in the order Brassicales

  2017cites this paper
• Pain Management in Horses.

  2017cites this paper
• Soluble epoxide hydrolase as a therapeutic target for pain, inflammatory and neurodegenerative diseases☆

  2017cites this paper
• Soluble epoxide hydrolase as a therapeutic target for pain , in fl ammatory and neurodegenerative diseases ☆

  2017cites this paper
• Multimodal analgesia, a fashionable term or evidence‐based medicine?

  2017cites this paper
• Synthesis and properties of symmetrical N,N'-Bis(R-adamantan-1-yl)ureas as target-oriented soluble epoxide hydrolase (sEH) inhibitors

  2017cites this paper
• Systematic pain assessment in horses.

  2016cites this paper
• Effect of a Soluble Epoxide Hydrolase Inhibitor , UC 1728 , on LPS-Induced Uveitis in the Rabbit Abbreviations

  2016cites this paper
• Effect of a Soluble Epoxide Hydrolase Inhibitor, UC1728, on LPS-Induced Uveitis in the Rabbit

  2016cites this paper
• The 2014 Bernard B. Brodie Award Lecture—Epoxide Hydrolases: Drug Metabolism to Therapeutics for Chronic Pain

  2015influential citation
• Effect of PO Administered Gabapentin on Chronic Lameness in Horses

  2015cites this paper
• Identification of potent inhibitors of the chicken soluble epoxide hydrolase.

  2015cites this paper
• FAAH and soluble epoxide hydrolase inhibitors are ynergistically antinociceptive

  2015cites this paper
• A multimodal disease modifying approach to treat neuropathic pain--inhibition of soluble epoxide hydrolase (sEH).

  2015cites this paper
• Acute equine laminitis: Exciting prospects afoot.

  2015cites this paper
• Pharmacological inhibition of soluble epoxide hydrolase prevents renal interstitial fibrogenesis in obstructive nephropathy.

  2015cites this paper
• In vitro and in vivo metabolism of N-adamantyl substituted urea-based soluble epoxide hydrolase inhibitors.

  2015cites this paper
• Peripheral FAAH and soluble epoxide hydrolase inhibitors are synergistically antinociceptive.

  2015cites this paper
• Potent Natural Soluble Epoxide Hydrolase Inhibitors from Pentadiplandra brazzeana Baillon: Synthesis, Quantification, and Measurement of Biological Activities In Vitro and In Vivo

  2015cites this paper
• Endoplasmic reticulum stress in the peripheral nervous system is a significant driver of neuropathic pain

  2015cites this paper
• Soluble Epoxide Hydrolase Inhibitors: New Molecules with Potential for Use in Veterinary Medicine

  2014cites this paper
• Pain control in horses: what do we really know?

  2014cites this paper
• Prostaglandins and Other Lipid Mediators eview he role of long chain fatty acids and their epoxide metabolites in ociceptive signaling

  2014cites this paper
• Optimized Inhibitors of Soluble Epoxide Hydrolase Improve in Vitro Target Residence Time and in Vivo Efficacy

  2014cites this paper
• Lipid-metabolizing CYPs in the regulation and dysregulation of metabolism.

  2014cites this paper
• Soluble epoxide hydrolase inhibitor, t‐TUCB, protects against myocardial ischaemic injury in rats

  2014cites this paper
• A Lipid Gate for the Peripheral Control of Pain

  2014cites this paper
• Science-in-brief: Equine laminitis research: milestones and goals.

  2014cites this paper
• Title Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacy Permalink

  2014cites this paper
• Stabilized epoxygenated fatty acids regulate inflammation, pain, angiogenesis and cancer.

  2014cites this paper
• Soluble epoxide hydrolase inhibition is antinociceptive in a mouse model of diabetic neuropathy.

  2014cites this paper
• The role of long chain fatty acids and their epoxide metabolites in nociceptive signaling.

  2014cites this paper
• Pain management for laminitis

  2013cites this paper
• Epoxy Fatty Acids and Inhibition of the Soluble Epoxide Hydrolase Selectively Modulate GABA Mediated Neurotransmission to Delay Onset of Seizures

  2013cites this paper
• SOLUBLE EPOXIDE HYDROLASE: A NOVEL THERAPEUTIC TARGET FOR METABOLIC SYNDROME

  year unknowncites this paper